Advertisement

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Published:March 21, 2016DOI:https://doi.org/10.1016/j.dld.2016.02.008

      Abstract

      Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent jury. The statements presented here highlight strengths and weaknesses of current laboratory tests to assess bleeding and thrombotic risk in cirrhotic patients, the pathophysiology of hemostatic perturbations in this condition, and outline the optimal management of bleeding and thrombosis in patients with liver cirrhosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tripodi A.
        • Salerno F.
        • Chantarangkul V.
        • et al.
        Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.
        Hepatology. 2005; 41: 553-558
        • Lisman T.
        • Bongers T.N.
        • Adelmeijer J.
        • et al.
        Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.
        Hepatology. 2006; 44: 53-61
        • Lisman T.
        • Leebeek F.W.
        • Mosnier L.O.
        • et al.
        Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
        Gastroenterology. 2001; 121: 131-139
        • Tripodi A.
        • Mannucci P.M.
        Mechanisms of disease. The coagulopathy of chronic liver disease.
        New England Journal of Medicine. 2011; 365: 147-156
        • Violi F.
        • Basili S.
        • Raparelli V.
        • et al.
        Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction.
        Journal of Hepatology. 2011; 55: 1415-1427
        • Violi F.
        • Leo R.
        • Vezza E.
        • et al.
        Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. Coagulation Abnormalities in Cirrhosis Study Group.
        Journal of Hepatology. 1994; 20: 531-536
        • Boberg K.M.
        • Brosstad F.
        • Egeland T.
        • et al.
        Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy?.
        Thrombosis and Haemostasis. 1999; 81: 378-381
        • Basili S.
        • Ferro D.
        • Leo R.
        • et al.
        Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. Coagulation Abnormalities in Liver Cirrhosis.
        Journal of Hepatology. 1996; 24: 574-580
        • Cosmi B.
        • Alatri A.
        • Cattaneo M.
        • et al.
        Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures.
        Thrombosis Research. 2009; 124: e6-e12
        • De Franchis R.
        • Arcidiacono P.G.
        • Carpinelli L.
        • et al.
        Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study.
        Hepatology. 1993; 18: 1102-1107
        • Giannini E.G.
        • Savarino V.
        Thrombocytopenia in liver disease.
        Current Opinion in Hematology. 2008; 15: 473-480
        • Tripodi A.
        • Primignani M.
        • Chantarangkul V.
        • et al.
        Thrombin generation in patients with cirrhosis: the role of platelets.
        Hepatology. 2006; 44: 440-445
        • Seeff L.B.
        • Everson G.T.
        • Morgan T.R.
        • et al.
        Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
        Clinical Gastroenterology and Hepatology. 2010; 8: 877-883
        • Tripodi A.
        • Primignani M.
        • Chantarangkul V.
        • et al.
        Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion.
        Liver International. 2013; 33: 362-367
        • Ewe K.
        Bleeding after liver biopsy does not correlate with indices of peripheral coagulation.
        Digestive Diseases and Sciences. 1981; 26: 388-393
        • McGill D.B.
        • Rakela J.
        • Zinsmeister A.R.
        • et al.
        A 21-year experience with major hemorrhage after percutaneous liver biopsy.
        Gastroenterology. 1990; 99: 1396-1400
        • Diaz L.K.
        • Teruya J.
        Liver biopsy.
        New England Journal of Medicine. 2001; 344: 2030
        • Terjung B.
        • Lemnitzer I.
        • Dumoulin F.L.
        • et al.
        Bleeding complications after percutaneous liver biopsy: an analysis of risk factors.
        Digestion. 2003; 67: 138-145
        • Grabau C.M.
        • Crago S.F.
        • Hoff L.K.
        • et al.
        Performance standards for therapeutic abdominal paracentesis.
        Hepatology. 2004; 40: 484-488
        • Segal J.B.
        • Dzik W.H.
        Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review.
        Transfusion. 2005; 45: 1413-1425
        • Boks A.L.
        • Brommer E.J.
        • Schalm S.W.
        • et al.
        Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage.
        Hepatology. 1986; 6: 79-86
        • Vieira da Rocha E.C.
        • D’Amico E.A.
        • Caldwell S.H.
        • et al.
        A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation.
        Clinical Gastroenterology and Hepatology. 2009; 7: 988-993
        • Bosch J.
        • Thabut D.
        • Bendtsen F.
        • et al.
        Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial.
        Gastroenterology. 2004; 127: 1123-1130
        • Bosch J.
        • Thabut D.
        • Albillos A.
        • et al.
        Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial.
        Hepatology. 2008; 47: 1604-1614
        • Lodge J.P.
        • Jonas S.
        • Jones R.M.
        • et al.
        Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.
        Liver Transplantation. 2005; 11: 973-979
        • Planinsic R.M.
        • van der Meer J.
        • Testa G.
        • et al.
        Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease.
        Liver Transplantation. 2005; 11: 895-900
        • Wang S.C.
        • Lin H.T.
        • Chang K.Y.
        • et al.
        Use of higher thromboelastogram transfusion values is not associated with greater blood loss in liver transplant surgery.
        Liver Transplantation. 2012; 18: 1254-1258
        • Wang S.C.
        • Shieh J.F.
        • Chang K.Y.
        • et al.
        Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial.
        Transplantation Proceedings. 2010; 42: 2590-2593
        • Tripodi A.
        • Primignani M.
        • Chantarangkul V.
        • et al.
        An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis.
        Gastroenterology. 2009; 137: 2105-2111
        • Violi F.
        • Ferro D.
        • Basili S.
        • et al.
        Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis.
        Hepatology. 1992; 15: 672-676
        • Caldwell S.H.
        • Hoffman M.
        • Lisman T.
        • et al.
        Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management.
        Hepatology. 2006; 44: 1039-1046
        • Colucci M.
        • Binetti B.M.
        • Branca M.G.
        • et al.
        Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
        Hepatology. 2003; 38: 230-237
        • Rijken D.C.
        • Kock E.L.
        • Guimarães A.H.
        • et al.
        Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests.
        Journal of Thrombosis and Haemostasis. 2012; 10: 2116-2122
        • Qi X.
        • Chen H.
        • Han G.
        Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis.
        American Journal of the Medical Sciences. 2013; 346: 38-44
        • Amitrano L.
        • Brancaccio V.
        • Guardascione M.A.
        • et al.
        Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis.
        Hepatology. 2000; 31: 345-348
        • Martinelli I.
        • Primignani M.
        • Aghemo A.
        • et al.
        High levels of factor VIII and risk of extra-hepatic portal vein obstruction.
        Journal of Hepatology. 2009; 50: 916-922
        • Tripodi A.
        • Primignani M.
        • Lemma L.
        • et al.
        Detection of the imbalance of pro- vs anti-coagulant factors in cirrhosis by a simple laboratory method.
        Hepatology. 2010; 52: 249-255
        • Trotter J.F.
        • Brimhall B.
        • Arjal R.
        Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation.
        Liver Transplantation. 2004; 10: 995-1000
        • Tripodi A.
        • Chantarangkul V.
        • Mannucci P.M.
        The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions.
        Journal of Thrombosis and Haemostasis. 2008; 6: 243-248
        • Tripodi A.
        • Chantarangkul V.
        • Primignani M.
        • et al.
        The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation.
        Hepatology. 2007; 46: 520-527
        • Bellest L.
        • Eschwege V.
        • Poupon R.
        • et al.
        A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology.
        Hepatology. 2007; 46: 528-534
        • Northup P.G.
        • McMahon M.M.
        • Ruhl A.P.
        • et al.
        Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism.
        American Journal of Gastroenterology. 2006; 101: 1524-1528
        • Søgaard K.K.
        • Horváth-Puhó E.
        • Grønbaek H.
        • et al.
        Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study.
        American Journal of Gastroenterology. 2009; 104: 96-101
        • Rodriguez-Castro K.I.
        • Simioni P.
        • Burra P.
        • et al.
        Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis.
        Liver International. 2012; 32: 1465-1476
        • Bechmann L.P.
        • Wichert M.
        • Kröger K.
        • et al.
        Dosing and monitoring of low-molecular-weight heparin in cirrhotic patients.
        Liver International. 2011; 31: 1064
        • Lisman T.
        • Porte R.J.
        Towards a rational use of low-molecular-weight heparin in patients with cirrhosis.
        Liver International. 2011; 31: 1063
        • Senzolo M.
        • Rodriguez Kryssia I.
        • Rossetto V.
        • et al.
        Increased anticoagulant response to low molecular weight heparin in plasma from patients with advanced cirrhosis.
        Journal of Thrombosis and Haemostasis. 2012; 10: 1823-1829
        • Villa E.
        • Cammà C.
        • Marietta M.
        • et al.
        Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
        Gastroenterology. 2012; 143: 1253-1260
        • Louie K.S.
        • Micallef J.M.
        • Pimenta J.M.
        • et al.
        Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review.
        Journal of Viral Hepatitis. 2011; 18: 1-7
        • Weksler B.B.
        The pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease.
        Alimentary Pharmacology and Therapeutics. 2007; 26: 13-19
        • Latvala J.
        • Parkkila S.
        • Niemelä O.
        Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells.
        Alcoholism, Clinical and Experimental Research. 2004; 28: 619-624
        • Torres Duarte A.P.
        • Dong Q.S.
        • Young J.
        • et al.
        Inhibition of platelet aggregation in whole blood by alcohol.
        Thrombosis Research. 1995; 78: 107-115
        • Zhang Q.H.
        • Das K.
        • Siddiqui S.
        • et al.
        Effects of acute, moderate ethanol consumption on human platelet aggregation in platelet-rich plasma and whole blood.
        Alcoholism, Clinical and Experimental Research. 2000; 24: 528-534
        • Seth D.
        • Hogg P.J.
        • Gorrell M.D.
        • et al.
        Direct effects of alcohol on hepatic fibrinolytic balance: implications for alcoholic liver disease.
        Journal of Hepatology. 2008; 48: 614-627
        • Pieters M.
        • Vorster H.H.
        • Jerling J.C.
        • et al.
        The effect of ethanol and its metabolism on fibrinolysis.
        Thrombosis and Haemostasis. 2010; 104: 724-733
        • Sengal H.
        • Cottam S.
        • Potter D.
        • et al.
        Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver diseases and during orthotopic liver transplantation.
        Hepatology. 1997; 25: 683-688
        • Pihusch R.
        • Rank A.
        • Gohring P.
        • et al.
        Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease.
        Journal of Hepatology. 2002; 37: 548-555
        • Biagini M.R.
        • Tozzi A.
        • Marcucci R.
        • et al.
        Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis.
        World Journal of Gastroenterology. 2006; 12: 1607-1612
        • Tripodi A.
        • Fracanzani A.L.
        • Primignani M.
        • et al.
        Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
        Journal of Hepatology. 2014; 61: 148-154
        • Sayed D.
        • Amin N.F.
        • Galal G.M.
        Monocyte–platelet aggregates and platelet micro-particles in patients with post-hepatitic liver cirrhosis.
        Thrombosis Research. 2010; 125: e228-e233
        • Wiest R.
        • Groszmann R.J.
        The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.
        Hepatology. 2002; 35: 478-491
        • Annie-Jeyachristy S.
        • Geetha A.
        • Surendran R.
        Changes in the level of cytosolic calcium, nitric oxide and nitric oxide synthase activity during platelet aggregation: an in vitro study in platelets from normal subjects and those with cirrhosis.
        Journal of Biosciences. 2008; 33: 45-53
        • Berzigotti A.
        • Erice E.
        • Gilabert R.
        • et al.
        Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis.
        American Journal of Gastroenterology. 2013; 108: 75-82
        • Albornoz L.
        • Alvarez D.
        • Otaso J.C.
        • et al.
        Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels.
        Journal of Hepatology. 1999; 30: 451-455
        • Ferlitsch M.
        • Reiberger T.
        • Hoke M.
        • et al.
        Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
        Hepatology. 2012; 56: 1439-1447
        • La Mura V.
        • Reverter J.C.
        • Flores-Arroyo A.
        • et al.
        Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
        Gut. 2011; 60: 1133-1138
        • Wannhoff A.
        • Müller O.J.
        • Friedrich K.
        • et al.
        Effects of increased von Willebrand factor levels on primary hemostasis in thrombocytopenic patients with liver cirrhosis.
        PLOS ONE. 2014; 9: e112583
        • Ferro D.
        • Quintarelli C.
        • Lattuada A.
        • et al.
        High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.
        Hepatology. 1996; 23: 1377-1383
        • Borzio M.
        • Salerno F.
        • Piantoni L.
        • et al.
        Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study.
        Digestive and Liver Disease. 2001; 33: 41-48
        • Moreau R.
        • Jalan R.
        • Gines P.
        • et al.
        Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.
        Gastroenterology. 2013; 144: 1426-1437
        • Vincent J.L.
        • Yagushi A.
        • Pradier O.
        Platelet function in sepsis.
        Critical Care Medicine. 2002; 30: S313-S317
        • Ferro D.
        • Basili S.
        • Lattuada A.
        • et al.
        Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant activation.
        Italian Journal of Gastroenterology and Hepatology. 1997; 29: 434-440
        • Grignani G.
        • Maiolo A.
        Cytokines and hemostasis.
        Haematologica. 2000; 85: 967-972
        • Amitrano L.
        • Guardascione M.A.
        • Brancaccio V.
        • et al.
        Coagulation disorders in liver disease.
        Seminars in Liver Disease. 2002; 22: 83-96
        • Montalto P.
        • Vlachogiannakos J.
        • Cox D.J.
        • et al.
        Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study.
        Journal of Hepatology. 2002; 37: 463-470
        • Zambruni A.
        • Thalheimer U.
        • Leandro G.
        • et al.
        Thromboelastography with citrated blood: comparability with native blood, stability of citrate storage and effect of repeated sampling.
        Blood Coagulation and Fibrinolysis. 2004; 15: 103-107
        • Senzolo M.
        • Riddell A.
        • Tuddenham E.
        • et al.
        Endogenous heparinoids contribute to coagulopathy in patients with liver disease.
        Journal of Hepatology. 2008; 48: 371-372
        • Plessier A.
        • Denninger M.H.
        • Consigny Y.
        • et al.
        Coagulation disorders in patients with cirrhosis and severe sepsis.
        Liver International. 2003; 23: 440-448
        • Reuken P.A.
        • Kussmann A.
        • Kiehntopf M.
        • et al.
        Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
        Liver International. 2015; 35: 37-45
        • Violi F.
        • Ferro D.
        • Basili S.
        • et al.
        Ongoing prothrombotic state in the portal circulation of cirrhotic patients.
        Thrombosis and Haemostasis. 1997; 77: 44-47
        • Soares-Weiser K.
        • Brezis M.
        • Tur-Kapsa R.
        • et al.
        Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials.
        Scandinavian Journal of Gastroenterology. 2003; 38: 193-200
        • Hou M.C.
        • Lin H.C.
        • Liu T.T.
        • et al.
        Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial.
        Hepatology. 2004; 39: 746-753
        • Piano S.
        • Rosi S.
        • Maresio G.
        • et al.
        Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites.
        Journal of Hepatology. 2013; 59: 482-489
        • Fagundes C.
        • Barreto R.
        • Guevara M.
        • et al.
        A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis.
        Journal of Hepatology. 2013; 59: 474-481
        • Go A.S.
        • Chertow G.M.
        • Fan D.
        • et al.
        Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
        New England Journal of Medicine. 2004; 351: 1296-1305
        • Mahmoodi B.K.
        • Gansevoort R.T.
        • Næss I.A.
        • et al.
        Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts.
        Circulation. 2012; 126: 1964-1971
        • Lutz J.
        • Menke J.
        • Sollinger D.
        • et al.
        Haemostasis in chronic kidney disease.
        Nephrology, Dialysis, Transplantation. 2014; 29: 29-40
        • De Gottardi A.
        • Thévenot T.
        • Spahr L.
        • et al.
        Risk of complications after diagnostic paracentesis in cirrhotic patients: a prospective study.
        Clinical Gastroenterology and Hepatology. 2009; 7: 906-909
        • Pache I.
        • Bilodeau M.
        Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease.
        Alimentary Pharmacology and Therapeutics. 2005; 21: 525-529
        • Lin C.H.
        • Shih F.Y.
        • Ma M.H.
        • et al.
        Should bleeding tendency deter abdominal paracentesis.
        Digestive and Liver Disease. 2005; 37: 946-951
        • Webster S.T.
        • Brown K.L.
        • Lucey M.R.
        • et al.
        Hemorrhagic complications of large volume abdominal paracentesis.
        American Journal of Gastroenterology. 1996; 91: 366-368
        • Castellote J.
        • Xiol X.
        • Cortés-Beut R.
        • et al.
        Complications of thoracentesis in cirrhotic patients with pleural effusion.
        Revista Espanola de Enfermedades Digestivas. 2001; 93: 566-575
        • Xiol X.
        • Castellote J.
        • Cortes-Beut R.
        • et al.
        Usefulness and complications of thoracentesis in cirrhotic patients.
        American Journal of Medicine. 2001; 111: 67-69
        • Piccinino F.
        • Sagnelli E.
        • Pasquale G.
        • et al.
        Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.
        Journal of Hepatology. 1986; 2: 165-173
        • Actis G.C.
        • Olivero A.
        • Lagget M.
        • et al.
        The practice of percutaneous liver biopsy in a gastrohepatology day hospital: a retrospective study on 835 biopsies.
        Digestive Diseases and Sciences. 2007; 52: 2576-2579
        • Caturelli E.
        • Giacobbe A.
        • Facciorusso D.
        • et al.
        Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site.
        American Journal of Gastroenterology. 1996; 91: 1318-1321
        • West J.
        • Card T.R.
        Reduced mortality rates following elective percutaneous liver biopsies.
        Gastroenterology. 2010; 139: 1230-1237
        • Kalambokis G.
        • Manousou P.
        • Vibhakorn S.
        • et al.
        Transjugular liver biopsy—indications, adequacy, quality of specimens, and complications—a systematic review.
        Journal of Hepatology. 2007; 47: 284-294
        • Bosch J.
        • Abraldes J.G.
        • Berzigotti A.
        • et al.
        The clinical use of HVPG measurements in chronic liver disease.
        Nature Reviews Gastroenterology & Hepatology. 2009; 6: 573-582
        • Woolfson J.
        • John P.
        • Kamath B.
        • et al.
        Measurement of hepatic venous pressure gradient is feasible and safe in children.
        Journal of Pediatric Gastroenterology and Nutrition. 2013; 57: 634-637
        • Ward B.B.
        • Weideman E.M.
        Long-term postoperative bleeding after dentoalveolar surgery in the pretransplant liver failure patient.
        Journal of Oral and Maxillofacial Surgery. 2006; 64: 1469-1474
        • Perdigão J.P.
        • de Almeida P.C.
        • Rocha T.D.
        • et al.
        Postoperative bleeding after dental extraction in liver pretransplant patients.
        Journal of Oral and Maxillofacial Surgery. 2012; 70: e177-e184
        • Vanbiervliet G.
        • Giudicelli-Bornard S.
        • Piche T.
        • et al.
        Predictive factors of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients: a case–control study.
        Alimentary Pharmacology and Therapeutics. 2010; 32: 225-232
        • Lee S.
        • Park S.J.
        • Cheon J.H.
        • et al.
        Child-Pugh score is an independent risk factor for immediate bleeding after colonoscopic polypectomy in liver cirrhosis.
        Yonsei Medical Journal. 2014; 55: 225-232
        • Jeon J.W.
        • Shin H.P.
        • Lee J.I.
        • et al.
        The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis.
        Surgical Endoscopy. 2012; 11: 3258-3263
        • Livraghi T.
        • Meloni F.
        • Di Stasi M.
        • et al.
        Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?.
        Hepatology. 2008; 47: 82-89
        • Cammà C.
        • Di Marco V.
        • Orlando A.
        • et al.
        Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study.
        Journal of Hepatology. 2005; 42: 535-540
        • Shiina S.
        • Teratani T.
        • Obi S.
        • et al.
        A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.
        Gastroenterology. 2005; 129: 122-130
        • Goto E.
        • Tateishi R.
        • Shiina S.
        • et al.
        Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors.
        Journal of Clinical Gastroenterology. 2010; 44: 374-380
        • McCluskey S.A.
        • Karkouti K.
        • Wijeysundera D.N.
        • et al.
        Derivation of a risk index for the prediction of massive blood transfusion in liver transplantation.
        Liver Transplantation. 2006; 12: 1584-1593
        • Massicotte L.
        • Beaulieu D.
        • Thibeault L.
        • et al.
        Coagulation defects do not predict blood product requirements during liver transplantation.
        Transplantation. 2008; 85: 956-962
        • Massicotte L.
        • Denault A.Y.
        • Beaulieu D.
        • et al.
        Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center.
        Transplantation. 2012; 93: 1276-1281
        • Esmat Gamil M.
        • Pirenne J.
        • Van Malenstein H
        • et al.
        Risk factors for bleeding and clinical implications in patients undergoing liver transplantation.
        Transplantation Proceedings. 2012; 44: 2857-2860
        • Kubo S.
        • Takemura S.
        • Yamamoto S.
        • et al.
        Risk factors for massive blood loss during liver resection for hepatocellular carcinoma in patients with cirrhosis.
        Hepato-Gastroenterology. 2007; 54: 830-833
        • Delis S.
        • Bakoyiannis A.
        • Madariaga J.
        • et al.
        Laparoscopic cholecystectomy in cirrhotic patients: the value of MELD score and Child-Pugh classification in predicting outcome.
        Surgical Endoscopy. 2010; 24: 407-412
        • da Silveira E.B.
        Outcome of cirrhotic patients undergoing cholecystectomy: applying Bayesian analysis in gastroenterology.
        Journal of Gastroenterology and Hepatology. 2006; 21: 958-962
        • Ammar S.A.
        Management of complicated umbilical hernias in cirrhotic patients using permanent mesh: randomized clinical trial.
        Hernia. 2010; 14: 35-38
        • Carbonell A.M.
        • Wolfe L.G.
        • De Maria E.J.
        Poor outcomes in cirrhosis-associated hernia repair: a nationwide cohort study of 32,033 patients.
        Hernia. 2005; 9: 353-357
        • Hedner U.
        • Lee C.A.
        First 20 years with recombinant FVIIa (NoveSeven).
        Haemophilia. 2010; 17: e172-e182
        • Shao Y.F.
        • Yang J.M.
        • Chau G.Y.
        • et al.
        Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial.
        American Journal of Surgery. 2006; 191: 245-249
        • Bernstein D.E.
        • Jeffers L.
        • Erhardtsen E.
        • et al.
        Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study.
        Gastroenterology. 1997; 113: 1930-1937
        • Chuansumrit A.
        • Treepongkaruna S.
        • Phuapradit P.
        Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases.
        Thrombosis and Haemostasis. 2001; 85: 748-749
        • Chuansumrit A.
        • Chantarojanasiri T.
        • Isarangkura P.
        • et al.
        Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation.
        Blood Coagulation and Fibrinolysis. 2000; 11: s101-s105
        • Jeffers L.
        • Chalasani N.
        • Balart L.
        • et al.
        Safety and efficacy of recombinant Factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy.
        Gastroenterology. 2002; 123: 118-126
        • Romero-Castro R.
        • Jimenez-Saenz M.
        • Pellicer-Bautista F.
        • et al.
        Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices.
        Clinical Gastroenterology and Hepatology. 2004; 2: 78-84
        • Lodge J.P.A.
        • Jonas S.
        • Oussoultzoglou E.
        • et al.
        Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.
        Anesthesiology. 2005; 102: 269-275
        • Chavez-Tapia N.C.
        • Alfaro-Lara R.
        • Tellez-Avila F.
        • et al.
        Prophylactic activated recombinant factor VII in liver resection and liver transplantation: systematic review and meta-analysis.
        PLoS ONE. 2011; 6: e22581
        • Peck-Radosavljenic M.
        Thrombocytopenia in liver disease.
        Canadian Journal of Gastroenterology. 2000; 14: 60D-66D
        • Poordad F.
        Thrombocytopenia in chronic liver disease.
        Alimentary Pharmacology and Therapeutics. 2007; 26: 5-11
        • Afdhal N.
        • McHutchison J.
        • Brown R.
        • et al.
        Thrombocytopenia associated with chronic liver disease.
        Journal of Hepatology. 2008; 48: 1000-1007
        • Violi F.
        • Pignatelli P.
        Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
        New England Journal of Medicine. 2012; 367: 2056
        • Luengo J.I.
        • Duffy K.J.
        • Shaw A.N.
        • et al.
        Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia.
        Blood. 2004; 104: 2910A
        • Jenkins J.M.
        • Williams D.
        • Deng Y.
        • et al.
        Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
        Blood. 2007; 109: 4739-4741
        • Sellers T.
        • Hart T.
        • Semanik M.
        • et al.
        Pharmacology and safety of SB-497115- GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs.
        Blood. 2004; 104: 2063A
        • Afdhal H.
        • Dusheiko G.M.
        • Giannini E.G.
        • et al.
        Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
        Gastroenterology. 2014; 146: 442-451
        • Afdhal N.H.
        • Giannini E.G.
        • Tayyab G.
        • et al.
        Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
        New England Journal of Medicine. 2012; 367: 716-724
        • Martí-Carvajal A.J.
        • Solà I.
        Vitamin K for upper gastrointestinal bleeding in patients with acute or chronic liver diseases.
        The Cochrane Database of Systematic Reviews. 2012; 9: CD004792
        • Pereira S.P.
        • Rowbotham D.
        • Fitt D.
        • et al.
        Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease.
        Journal of Hepatology. 2005; 42: 365-370
        • Saja M.F.
        • Abdo A.
        • Sanai F.M.
        • et al.
        The coagulopathy of liver disease: does vitamin K help?.
        Blood Coagulation and Fibrinolysis. 2013; 24: 10-17
        • Everson G.T.
        A hepatologist's perspective on the management of coagulation disorders before liver transplantation.
        Liver Transplantation and Surgery. 1997; 3: 646-652
        • Maltz G.S.
        • Siegel J.E.
        • Carson J.L.
        Hematologic management of gastrointestinal bleeding.
        Gastroenterology Clinics of North America. 2000; 29: 169-187
        • Mueller M.M.
        • Bomke B.
        • Seifried E.
        Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases.
        Thrombosis Research. 2002; 107: S9-S17
        • Vlavianos P.
        • Mac M.P.
        • Williamns R.
        • et al.
        Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension.
        Clinical Science (London). 1999; 96: 475-481
        • Martin D.J.
        • Lucas C.E.
        • Ledgerwood A.M.
        • et al.
        Fresh frozen plasma supplement to massive red blood cell transfusion.
        Annals of Surgery. 1985; 202: 505-511
        • Gazzard B.G.
        • Henderson J.M.
        • Williams R.
        The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy.
        Gut. 1975; 16: 621-625
        • Youssef W.I.
        • Salazar F.
        • Dasarathy S.
        • et al.
        Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study.
        American Journal of Gastroenterology. 2003; 98: 1391-1394
        • Spector I.
        • Corn M.
        • Ticktin H.E.
        Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease.
        New England Journal of Medicine. 1966; 275: 1032-1037
        • Tripodi A.
        • Chantarangkul V.
        • Primignani M.
        • et al.
        Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma.
        Internal and Emergency Medicine. 2012; 7: 139-144
        • Mannucci P.M.
        • Franchi F.
        • Dioguardi N.
        Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates.
        Lancet. 1976; 2: 542-545
        • Sorensen B.
        • Spahn D.R.
        • Innerhofer P.
        • et al.
        Clinical review: Prothrombin complex concentrates: evaluation of safety and thrombogenicity.
        Critical Care. 2011; 15: 201
        • Dentali F.
        • Marchesi C.
        • Pierfranceschi M.G.
        • et al.
        Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.
        Thrombosis and Haemostasis. 2011; 106: 429-438
        • Lorenz R.
        • Kienast J.
        • Otto U.
        • et al.
        Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage.
        European Journal of Gastroenterology and Hepatology. 2003; 15: 15-20
        • Mannucci P.M.
        • Vicente V.
        • Vianello L.
        • et al.
        Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time.
        Blood. 1986; 67: 1148-1153
        • Burroughs A.K.
        • Matthews K.
        • Qadiri M.
        • et al.
        Desmopressin and bleeding time in patients with cirrhosis.
        British Medical Journal. 1985; 291: 1377-1381
        • Wong A.Y.
        • Irwin M.G.
        • Hui T.W.
        • et al.
        Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy.
        Canadian Journal of Anaesthesia. 2003; 50: 14-20
        • Stanca C.M.
        • Montazem A.H.
        • Lawal A.
        • et al.
        Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial.
        Journal of Oral and Maxillofacial Surgery. 2010; 68: 138-143
        • Shore-Lesserson L.
        Point-of-care coagulation monitoring for cardiovascular patients: past and present.
        Journal of Cardiothoracic and Vascular Anesthesia. 2002; 16: 99-106
        • Pereboom I.T.
        • de Boer M.T.
        • Porte R.J.
        • et al.
        Aprotinin and nafamostat mesilate in liver surgery: effect on blood loss.
        Digestive Surgery. 2007; 24: 282-287
        • Lentschener C.
        • Benhamou D.
        • Mercier F.J.
        • et al.
        Aprotinin reduces blood loss in patients undergoing elective liver resection.
        Anesthesia and Analgesia. 1997; 84: 875-881
        • Shimada M.
        • Matsumata T.
        • Shirabe K.
        • et al.
        Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
        Journal of the American College of Surgeons. 1994; 178: 498-502
        • Franchini M.
        • Mannucci P.M.
        Adjunct agents for bleeding.
        Current Opinion in Hematology. 2014; 21: 503-508
        • Dalmau A.
        • Sabate A.
        • Acosta F.
        • et al.
        Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation.
        Anesthesia and Analgesia. 2000; 91: 29-34
        • Wu C.C.
        • Ho W.M.
        • Cheng S.B.
        • et al.
        Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a blood transfusion-free hepatectomy.
        Annals of Surgery. 2006; 243: 173-180
        • Molenaar I.Q.
        • Warnaar N.
        • Groen H.
        • et al.
        Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis.
        American Journal of Transplantation. 2007; 7: 185-194
        • McCormick P.A.
        • Ooi H.
        • Crosbie O.
        Tranexamic acid for severe bleeding gastric antral vascular ectasia in cirrhosis.
        Gut. 1998; 42: 750-752
        • Garcia-Fuster M.J.
        • Abdlla N.
        • Fabia M.J.
        • et al.
        Venous thromboembolism and liver cirrhosis.
        Revista Espanola de Enfermedades Digestivas. 2008; 100: 259-262
        • Dabbagh O.
        • Oza A.
        • Prakash S.
        • et al.
        Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease.
        Chest. 2010; 137: 1145-1149
        • Huerta C.
        • Johansson S.
        • Wallander M.A.
        • et al.
        Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom.
        Archives of Internal Medicine. 2007; 167: 935-943
        • Gulley D.
        • Teal E.
        • Suvannasankha A.
        • et al.
        Deep vein thrombosis and pulmonary embolism in cirrhosis patients.
        Digestive Diseases and Sciences. 2008; 53: 3012-3017
        • Anthony Lizarraga W.
        • Dalia S.
        • Reinert S.E.
        • et al.
        Venous thrombosis in patients with chronic liver disease.
        Blood Coagulation and Fibrinolysis. 2010; 21: 431-435
        • Aldawood A.
        • Arabi Y.
        • Aljumah A.
        • et al.
        The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients.
        Thrombosis Journal. 2011; 9: 1-6
        • Lesmana C.R.
        • Inggriani S.
        • Cahyadinata L.
        • et al.
        Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition.
        Hepatology International. 2010; 4: 433-438
        • Walsh K.A.
        • Lewis D.A.
        • Clifford T.M.
        • et al.
        Risk factors for venous thromboembolism in patients with chronic liver disease.
        Annals of Pharmacotherapy. 2013; 47: 333-339
        • Wu H.
        • Nguyen G.C.
        Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study.
        Clinical Gastroenterology and Hepatology. 2010; 8: 800-805
        • Saleh T.
        • Matta F.
        • Alali F.
        • et al.
        Venous thromboembolism with chronic liver disease.
        American Journal of Medicine. 2011; 124: 64-68
        • Ali M.
        • Ananthakrishnan A.N.
        • McGinley E.L.
        • et al.
        Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis.
        Digestive Diseases and Sciences. 2011; 56: 2152-2159
        • Barclay S.M.
        • Jeffres M.N.
        • Nguyen K.
        • et al.
        Evaluation of pharmacologic prophylaxis for venous thromboembolism in patients with chronic liver disease.
        Pharmacotherapy. 2013; 33: 375-382
        • Intagliata N.M.
        • Henry Z.H.
        • Shah N.
        • et al.
        Prophylactic anticoagulation for deep venous thrombosis in hospitalized cirrhosis patients is safe and does not lead to increased bleeding events.
        Hepatology. 2011; 54: 1253A
        • Zocco M.A.
        • Stasio E.D.
        • Cristofaro R.D.
        • et al.
        Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.
        Journal of Hepatology. 2009; 51: 682-689
        • Maruyama H.
        • Okugawa H.
        • Takahashi M.
        • et al.
        De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes.
        American Journal of Gastroenterology. 2013; 108: 568-574
        • John B.V.
        • Konjeti R.
        • Aggarwal A.
        • et al.
        Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis.
        Annals of Hepatology. 2013; 12: 952-958
        • Nery F.
        • Chevret S.
        • Condat B.
        • et al.
        Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study.
        Hepatology. 2015; 61: 660-667
        • Violi F.
        • Ferro D.
        • Basili S.
        • et al.
        Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver.
        British Medical Journal. 1994; 309: 239-240
        • Amitrano L.
        • Guardascione M.A.
        • Brancaccio V.
        • et al.
        Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis.
        Journal of Hepatology. 2004; 40: 736-741
        • Robles R.
        • Fernandez J.A.
        • Hernández Q.
        • et al.
        Eversion thromboendovenectomy in organized portal vein thrombosis during liver transplantation.
        Clinical Transplantation. 2004; 18: 79-84
        • Fimognari F.L.
        • De Santis A.
        • Piccheri C.
        • et al.
        Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis.
        Journal of Laboratory and Clinical Medicine. 2005; 146: 238-243
        • Lendoire J.
        • Raffin G.
        • Cejas N.
        • et al.
        Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome.
        HPB (Oxford). 2007; 9: 352-356
        • Weber A.
        • Krebs S.
        • Lenhardt C.
        • et al.
        Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis.
        Hepatology Research. 2009; 39: 882-887
        • Girleanu I.
        • Stanciu C.
        • Cojocariu C.
        • et al.
        Natural course of nonmalignant partial portal vein thrombosis in cirrhotic patients.
        Saudi Journal of Gastroenterology. 2014; 20: 288-292
        • Berry K.
        • Taylor J.
        • Liou I.W.
        • et al.
        Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis.
        Clinical Gastroenterology and Hepatology. 2015; 13: 585-593
        • Tsochatzis E.A.
        • Senzolo M.
        • Germani G.
        • et al.
        Systematic review: portal vein thrombosis in cirrhosis.
        Alimentary Pharmacology and Therapeutics. 2010; 31: 366-374
        • Primignani M.
        Portal vein thrombosis, revisited.
        Digestive and Liver Disease. 2009; 42: 163-170
        • Garcia-Pagan J.C.
        • Valla D.C.
        Portal vein thrombosis: a predictable milestone in cirrhosis?.
        Journal of Hepatology. 2009; 51: 632-634
        • Politoske D.
        • Ralls P.
        • Korula J.
        Portal vein thrombosis following endoscopic variceal sclerotherapy. Prospective controlled comparison in patients with cirrhosis.
        Digestive Diseases and Sciences. 1996; 41: 185-190
        • Kawasaki S.
        • Henderson J.M.
        • Riepe S.P.
        • et al.
        Endoscopic variceal sclerosis does not increase the risk of portal venous thrombosis.
        Gastroenterology. 1992; 102: 206-215
        • Mangia A.
        • Margaglione M.
        • Cascavilla I.
        • et al.
        Anticardiolipin antibodies in patients with liver disease.
        American Journal of Gastroenterology. 1999; 94: 2983-2987
        • Romero Gomez M.
        • Suarez Garcia E.
        • Lopez Lacomba D.
        • et al.
        Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis.
        Journal of Clinical Gastroenterology. 2000; 31: 237-240
        • Amitrano L.
        • Guardascione M.A.
        • Ames P.R.
        • et al.
        Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation.
        Thrombosis and Haemostasis. 2006; 95: 221-223
        • Piscaglia F.
        • Gianstefani A.
        • Ravaioli M.
        • et al.
        Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation.
        Liver Transplantation. 2010; 16: 658-667
        • Rossi S.
        • Rosa L.
        • Ravetta V.
        • et al.
        Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems.
        American Journal of Roentgenology. 2006; 186: 1-11
        • Tarantino L.
        • Francica G.
        • Sordelli I.
        • et al.
        Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine needle biopsy.
        Abdominal Imaging. 2006; 31: 537-544
        • Yerdel M.A.
        • Gunson B.
        • Mirza D.
        • et al.
        Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome.
        Transplantation. 2000; 69: 1873-1881
        • Luca A.
        • Caruso S.
        • Milazzo M.
        Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis.
        Radiology. 2012; 265: 124-132
        • Senzolo M.
        • Sartori T.
        • Rossetto V.
        • et al.
        Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis.
        Liver International. 2012; 32: 919-927
        • Englesbe M.J.
        • Kubus J.
        • Muhammad W.
        • et al.
        Portal vein thrombosis and survival in patients with cirrhosis.
        Liver Transplantation. 2010; 16: 83-90
        • Rodríguez-Castro K.I.
        • Porte R.J.
        • Nadal E.
        • et al.
        Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review.
        Transplantation. 2012; 94: 1145-1153
        • Delgado M.G.
        • Seijo S.
        • Yepes I.
        • et al.
        Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis.
        Clinical Gastroenterology and Hepatology. 2012; 10: 776-783
        • Amitrano L.
        • Guardascione M.A.
        • Menchise A.
        • et al.
        Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.
        Journal of Clinical Gastroenterology. 2010; 44: 448-451
        • Francoz C.
        • Belghiti J.
        • Vilgrain V.
        • et al.
        Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation.
        Gut. 2005; 54: 691-697
        • Werner K.T.
        • Sando S.
        • Carey E.J.
        • et al.
        Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation.
        Digestive Diseases and Sciences. 2013; 58: 1776-1780
        • Francoz C.
        • Valla D.
        • Durand F.
        Portal vein thrombosis, cirrhosis, and liver transplantation.
        Journal of Hepatology. 2012; 57: 203-212
        • Congly S.E.
        • Lee S.S.
        Portal vein thrombosis: should anticoagulation be used?.
        Current Gastroenterology Reports. 2013; 15: 306
        • Kinjo N.
        • Kawanaka H.
        • Akahoshi T.
        • et al.
        Portal Vein thrombosis in liver cirrhosis.
        World Journal of Hepatology. 2014; 6: 64-71